Clinical breast cancer最新文献

{"title":"In Triple-Negative Breast Cancer: Correlation Among Metabolic Syndrome, S100A7/cPLA2 Expression and the Efficacy of Neoadjuvant Chemotherapy.","authors":"Chenhong Ma, Xue Fang, Wenwen Wang, Shuyu Ji, Huili Liu, Wenli Lv, Dabei Tang","doi":"10.1016/j.clbc.2025.02.014","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.014","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) has a poor prognosis. Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is a prognostic factor. This study aimed to find predictors of efficacy.</p><p><strong>Methods: </strong>A total of 266 TNBC patients treated with NAC were included. The relationship between MetS, S100A7/cPLA2 expression and clinicopathological features was investigated. The effect on pCR, clinical response, and disease-free survival (DFS) was observed. A cell co-culture model was established by the researchers to further assess the function of S100A7.</p><p><strong>Results: </strong>Correlation analysis revealed a strong association between the expressions of S100A7 and cPLA2, with both significantly higher in the MetS group compared to the non-MetS group. Logistic regression analysis indicated that MetS and S100A7/cPLA2 expressions were linked to pCR and clinical response. S100A7/cPLA2 served as an independent predictor of pCR, while cPLA2 was an independent predictor of clinical response. Survival analysis demonstrated that MetS and S100A7/cPLA2 were associated with an increased risk of disease progression. MP grading and clinical efficacy were independent predictors of DFS, with MetS and S100A7/cPLA2 expressions correlating with shortened DFS. In the co-culture model, S100A7 inhibited the NF-κB pathway, enhancing TNBC cell proliferation and invasion in the presence of macrophages, and promoting M2 macrophage polarization.</p><p><strong>Conclusion: </strong>S100A7/cPLA2 expression predicts a low pCR rate in TNBC patients undergoing NAC and may serve as a potential mechanistic biomarker linking MetS with altered NAC efficacy in TNBC, warranting further investigation and intervention.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Outcomes in Immediate Prepectoral Reconstruction of Large and Ptotic Breast: The Reliability of Fifth Anterior Intercostal Artery Perforator Flap.","authors":"Domenico Pagliara, Nicola Pili, Pietro Luciano Serra, Laurenza Schiavone, Corrado Rubino, Diego Ribuffo, Marzia Salgarello, Alberto Rancati","doi":"10.1016/j.clbc.2025.02.012","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.012","url":null,"abstract":"<p><strong>Background and objective: </strong>Conservative mastectomy is burdened by possible necrosis of the breast skin and nipple-areola complex, particularly among patients with macromastia and severe ptosis undergoing heterologous reconstruction. It is well known that anterior fifth intercostal artery perforator plays a critical role in nipple-areola complex blood supply. Our study investigates outcomes of large or ptotic breasts, undergoing immediate prepectoral direct-to-implant breast reconstruction covered by dermoadipose flap based on the fifth anterior intercostal artery perforator.</p><p><strong>Methods: </strong>We conducted a retrospective study on 70 consecutive patients who underwent skin-reducing mastectomy, with or without nipple preservation, using an inverted T-pattern. Setup of a dermo-adipose flap with an inferior pedicle, based on the anterior intercostal artery perforator of the fifth intercostal space was performed, according to preoperative Doppler ultrasound. Immediate breast reconstruction was performed using Microthane implants. We assessed rate of mastectomy flap necrosis (Mayo Clinic Classification), at 12 months follow up, pre- and postmastectomy satisfaction with breast, physical well-being of the chest with BREAST-Q questionnaire, and spinal pain using the McGill Pain Questionnaire.</p><p><strong>Results: </strong>No complications such as hematoma, seroma, or implant infections occurred. Ischemic complications were observed in 11 cases (13.9%), however, only in one case was implant removal necessary. Satisfaction with breast appearance, chest physical well-being, and the pain rating index all significantly improved postoperatively.</p><p><strong>Conclusions: </strong>Direct to implant reconstruction using the inferiorly pedicled flap based on the AICAP is a reliable and reproducible technique that offers favorable results with low complication rates in large or ptotic skin reducing mastectomies.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes\".","authors":"Yoonwon Kook, Sung Gwe Ahn","doi":"10.1016/j.clbc.2025.02.011","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.011","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the Assessment of Breast Cancer Surgery Information on YouTube.","authors":"Chenhong Li, Chengfei Du","doi":"10.1016/j.clbc.2025.02.010","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.010","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Chronic Pain and Breast Cancer: Insight From Genetic Correlation Analyses and 2-Sample Mendelian Randomization.","authors":"Haojie Yang, Xiaoyan Xie, Liling Lin, Zicong Tan, Zhongqi Liu, Yangfan Zhang, Fengtao Ji, Yuejuan Che","doi":"10.1016/j.clbc.2025.02.004","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.004","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate potential genetic causal relationships between chronic pain subtypes like migraine and multi-site chronic pain (MCP) and their impact on breast cancer occurrence and survival rates.</p><p><strong>Background: </strong>The association between chronic pain and breast cancer was reported before, yet the causal nature between them remained uncertain.</p><p><strong>Methods: </strong>Data on chronic pain and breast cancer were sourced from publicly available European genome-wide association study (GWAS) datasets. Genetic association between chronic pain and breast cancer phenotypes was assessed using linkage disequilibrium genetic correlation (LDSC). Colocalization analysis further identified potential shared causal variation. Based on Inverse variance weighted method, 2-sample Mendelian Randomization (MR) was conducted to investigate causal associations between migraine, MCP, and breast cancer or breast cancer survival. Sensitive analysis was conducted to ensure the absence of heterogeneity and horizontal pleiotropy.</p><p><strong>Results: </strong>LDSC demonstrated significant genetic correlations between migraine and both estrogen receptor-negative (ER-) and overall breast cancer, while also revealing a notable genetic association between MCP and ER- and ER+ breast cancer, as well as overall breast cancer. Through colocalization analysis, potential involvement of rs2183271, located in MLLT10 gene, in regulating MCP and ER+ breast cancer was identified. MR analysis revealed the association between migraine and elevated risk of ER- breast cancer (IVW, P = 4.95 × 10^-3). Cochran's Q test ensured the absence of heterogeneity and MR-PRESSO global test, MR-Egger intercept test ensured the absence of horizontal pleiotropy.</p><p><strong>Conclusion: </strong>Our results provided new insights into the role of migraine and MCP in breast cancer, paving the way for targeted preventive strategies and future investigations.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Growth Rate of Luminal and Nonluminal Invasive Breast Cancer Calculated on MRI Imaging.","authors":"Uwe Fischer","doi":"10.1016/j.clbc.2025.02.008","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.008","url":null,"abstract":"<p><strong>Purpose: </strong>Calculation of the size growth of different types of breast carcinoma based on follow-up data in breast MRI.</p><p><strong>Patients and methods: </strong>Patients were included if they had been diagnosed with an invasive breast carcinoma in the current MRI (aMRI), and had also undergone a breast MRI (pMRI) with unsuspicious findings (MR BIRADS 1 or 2) within 5 years prior to diagnosis. If retrospective analysis of pMRI revealed signs of the current carcinoma, a quantitative one-dimensional-analysis of size progression of the carcinoma over time was performed, and growth rates for different tumor types were calculated.</p><p><strong>Results: </strong>About 204 patients with 208 invasive breast carcinomas (74 luminal A, 105 luminal B, nonluminal 29) were included. In 129 carcinomas, there were signs of the current tumor in the pMRI. Based on the interval between pMRI and aMRI (average 21 months), the average tumor doubling time was 1126 days (3.1 years), 624 days (1.7 years), and 254 days (0.7 years) of luminal A, luminal B, and nonluminal. The average tumor size was 4.3 mm in the pMRI, and 9.5 mm in aMRI. In 79 cases, the pMRI showed no signs of the actual carcinoma. In this group, the average current tumor size was 8.5 mm.</p><p><strong>Conclusion: </strong>The study provides specific information on the growth rate of luminal and nonluminal breast cancer. According to this, early detection intervals for nonhigh-risk women using MRI of 2 to 3 years, and for high-risk (HR) women of 1 year appear reasonable. Data also provide a well-founded basis for medico-legal judgements.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Undertreatment With Chemotherapy Impact the Outcomes of Elderly Patients With Early-Stage Breast Cancer? A Real-World Data Analysis.","authors":"Jéssica Monteiro Vasconcellos, Renata Colombo Bonadio, Sofia Vidaurre Mendes, Bruna Zanin Orsi, Letícia Vecchi Leis, Ana Paula Messias, Otávio Augusto Moreira Noschang, Maurício Baptista Pereira, Pedro José Galvão Freire, Augusto Rodrigues de Araújo Neto, Erika Andrade Rocha, Theodora Karnakis, Laura Testa","doi":"10.1016/j.clbc.2025.02.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.007","url":null,"abstract":"<p><strong>Background: </strong>The management of breast cancer (BC) in elderly patients remains a topic of debate among specialists, with concerns regarding potential undertreatment. This study aimed to evaluate the impact of undertreatment on outcomes in older patients with early-stage BC.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed patients aged over 70 years with early breast cancer who were treated at an academic cancer center between 2009 and 2021.Indications for (neo)adjuvant chemotherapy (CT) were assessed based on institutional guidelines. Undertreatment was defined as patients who had an indication for CT but did not receive it. The study evaluated undertreatment rate, recurrence rate, disease-free survival, breast cancer-specific survival (BCSS), overall survival (OS), and prognostic factors.</p><p><strong>Results: </strong>A total of 1455 patients had early-stage BC. The majority of patients were between 70 and 80 years old (71%), had luminal tumors (79%), and mild comorbidities (60%). Of the 921 patients for whom (neo)adjuvant chemotherapy (CT) was indicated, 57% did not receive it, mainly due to age and comorbidities. The 5-year BCSS was 90.3% in the undertreated group compared to 86.3% in the CT group (P = .024). The 5-year OS was 76.3% in the undertreated group compared to 81% in the CT group (P = .389). Multivariable analysis identified predictors of worse OS, but undertreatment was not directly associated.</p><p><strong>Conclusion: </strong>Undertreatment rates were high in this older population, yet outcomes were not negatively impacted. Thus, not offering (neo)adjuvant CT may be a wise choice for selected elderly pts with early BC, taking into account their comorbidities and functional status.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of the COVID-19 Pandemic on the Diagnosis and Treatment of Breast Cancer at a Community Hospital.","authors":"Mariah Mack, Matthew McGee, Barbara Bennie, Andrea Arenz, Leah Dietrich","doi":"10.1016/j.clbc.2025.02.005","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.005","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic disrupted breast cancer care, potentially affecting diagnosis stage, time to treatment initiation, and treatment modalities. This study evaluated how pandemic-related restrictions affected these factors at a community hospital.</p><p><strong>Methods: </strong>We conducted a retrospective review of electronic health records for 941 patients diagnosed with breast cancer. Patients were categorized by diagnosis time. We used Kruskal-Wallis tests to compare median time to first treatment by modality, COX proportional hazard models to analyze time to treatment in relation to diagnosis time period and clinical stage, and Chi-square tests to evaluate changes in modality of first treatment and cancer stage.</p><p><strong>Results: </strong>Clinical stage at diagnosis varied significantly across time periods (P = .01), with more advanced stages during Peak-COVID and Post-Peak-COVID. Median time to first treatment increased during Peak-COVID (47 days) and Post-Peak-COVID (54 days) compared to Pre-COVID (38 days) (P < .001). Time to surgery as first treatment modality increased over the 3 periods (P < .001), while no significant differences were found for chemotherapy (P = .06) or hormone therapy (P = .28). The modality of first treatment shifted significantly (P < .001), with a decline in hormone therapy use during Peak-COVID, followed by an increase Post-Peak-COVID.</p><p><strong>Conclusions: </strong>Our study highlights the pandemic's impact on breast cancer care, demonstrating significant differences in clinical stage at diagnosis, time to first treatment, and modality of first treatment. These disparities persisted into 2022, reflecting lasting effects of pandemic-related disruptions. Addressing these delays is essential for mitigating care gaps in future times of healthcare disruption.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anesthetic Agents as Therapeutic Tools in Breast Cancer: Insights into Cancer Progression and Recurrence.","authors":"Jiaqiao Wu, Jindong Yang, Jiqing Duan","doi":"10.1016/j.clbc.2025.02.009","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.009","url":null,"abstract":"<p><p>Breast cancer (BC) remains one of the leading causes of cancer-related mortality worldwide, necessitating continuous advancements in therapeutic strategies. While anesthetic agents are traditionally used for managing pain and sedation during BC surgeries, emerging evidence suggests their potential influence on cancer progression and recurrence. This comprehensive review examines the role of various anesthetic agents as therapeutic tools in BC, exploring the molecular mechanisms underlying their interaction with tumor biology. The review categorizes anesthetics into volatile, intravenous, and local agents, discussing their differential effects on cancer cell proliferation, immune modulation, and metastatic potential. Key findings indicate that volatile anesthetics such as sevoflurane and isoflurane may promote tumor progression, whereas intravenous anesthetics like propofol exhibit anticancer properties. Local anesthetics, particularly lidocaine, and bupivacaine, show promise through voltage-gated sodium channel (VGSC) blockade, while opioids have mixed effects, with tramadol being less favorable in cancer settings. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ketorolac and diclofenac have demonstrated potential in reducing BC recurrence, and regional anesthesia techniques like paravertebral blocks may provide immunomodulatory benefits. Clinical studies assessing the correlation between anesthetic choice and BC recurrence suggest that perioperative anesthetic strategies may impact circulating tumor cells and postoperative metastasis. However, most findings are derived from preclinical and retrospective studies, highlighting the need for large-scale prospective trials. Future research should focus on tailoring anesthetic regimens to tumor biology and patient-specific factors, integrating anesthetic pharmacology into cancer care to improve both immediate surgical outcomes and long-term prognosis. This article underscores the need for a paradigm shift in anesthetic use, positioning it as a crucial player in BC treatment strategies.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of 10-Year Survival Between Patients With Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy and Patients With Initially Negative Nodes in Breast Cancer.","authors":"Jiwei Wang, Xing Wang, Yingjian He, Tianfeng Wang, Jinfeng Li, Zhaoqing Fan, Tao Ouyang","doi":"10.1016/j.clbc.2025.02.006","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.02.006","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to determine whether patients with cytologically proven node-positive disease who achieved axillary pathologic complete response (ypN0) after neoadjuvant chemotherapy (NAC) have similar survival outcomes to those with initially pathologically negative lymph nodes (pN0).</p><p><strong>Methods: </strong>Patients with cytologically proven node-positive breast cancer who achieved ypN0 after NAC and those with pN0 between June 2005 and March 2012 in a large cancer hospital were reviewed. The relapse-free survival (RFS), distant-disease-free survival (DDFS) and overall survival (OS) of the 2 groups were calculated and compared.</p><p><strong>Results: </strong>A total of 2285 patients, including 183 patients with ypN0 and 2102 patients with pN0, were included in this study. The median follow-up time for patients was 121 (range 2-182) months. The 10-year cumulative RFS was 79.7% for ypN0 patients and 90.2% for pN0 patients (log-rank P < .001). The 10-year cumulative DDFS was 81.4% for ypN0 patients and 92.2% for pN0 patients (log-rank P < .001). The 10-year cumulative OS was 86.3% for ypN0 patients and 94.0% for pN0 patients (log-rank P < .001). The multivariable Cox proportional hazards models showed that compared with pN0 patients, ypN0 patients had a 2.00-fold increase in the risk of recurrence (HR = 2.00, 95% CI, 1.33-3.01, P = .001), a 2.34-fold increase in the risk of distant recurrence (HR = 2.34, 95% CI, 1.52-3.62, P < .001) and a 2.10-fold increase in the risk of death (HR = 2.10, 95% CI, 1.25-3.53, P = .005).</p><p><strong>Conclusion: </strong>Patients with axillary pCR showed inferior RFS, DDFS and OS to patients with pN0.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}